Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on…
HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on…
Facility provides additional funding for next steps of the Company’s growth, including the expected launch of bezuclastinib in 2026 On…
Chris Ricaurte Appointed as Chief Financial Officer and Dan Bise Joins as EVP of Corporate Development and Strategy Reflects R1’s…
—Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— —Preparations for the Nebokitug PSC Phase…
Engages with Cytel’s Machine Learning Technology on Data Analysis and Phase 3 Trial DesignGLEN ALLEN, Va., June 11, 2025 (GLOBE…
ALAMEDA, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical…
Study met primary endpoint of safety and tolerability at all doses and secondary pharmacodynamic and pharmacokinetic endpoints after single subcutaneous…
-- PCRX-201 demonstrated sustained clinical efficacy with improvements in pain, stiffness, and function for up to three years – BRISBANE,…
RAD101 in U.S. Phase 2 clinical trial to distinguish between recurrent disease and treatment effect of brain metastases originating from…